ALKERMES (ALKS)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ALKS
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALKS | Independent Director; Chair | 63 | ["Served as President of Alkermes Pharma Ireland Limited","Chief Financial Officer of Elan Corporation","Chief Executive of Pembroke Capital Limited","Experience in managing corporate entities in Ireland","Chartered accountant","audit committee financial expert"] | ["Audit and Risk (C)","Financial Operating","Nominating and Corporate Governance","Audit and Risk (Chair)","Audit and Risk Committee","Financial Operating Committee","Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PRTA | Director | 63 | ["Scientific expertise in biopharmaceutical research and/or in relevant medical fields", "Experience in the design and implementation of clinical studies in support of drug development", "Experience with regulation in the healthcare industry", "Experience overseeing and driving strategic direction and growth of an organization", "Experience or expertise in financial accounting and reporting processes or the financial management of an organization", "Experience with legal and ethical and public policy issues in the healthcare industry", "Service on a public company board other than Prothena\u2019s", "Experience in capital market transactions or mergers and acquisitions", "Experience in attracting and retaining top talent and building organizational culture"] | ["Compensation Committee", "Nominating and Corporate Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Mr. Cooke served as our President and as President of Alkermes Pharma Ireland Limited ( APIL ), a wholly-owned subsidiary of the Company, from September 2011 until his retirement in March 2018. He became a member of our Board upon his retirement. In addition, Mr. Cooke has been chairman of the board of directors of APIL since September 2011. Mr. Cooke served as Executive Vice President of Elan Corporation, plc ( Elan ) and Head of Elan Drug Technologies from May 2007 to September 16, 2011 and as the Chief Financial Officer of Elan from July 2001 until May 2011. Mr. Cooke served as a director of Elan from May 2005 to September 16, 2011. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that, he held a number of senior finance positions in the banking and aviation industries. Mr. Cooke previously served on the board of directors of then publicly-traded healthcare companies UDG Healthcare plc from February 2019 to August 2021 and Endo International plc from July 2014 to April 2024. He is a chartered accountant. Qualifications and Skills: Mr. Cooke is an Irish citizen, resident in Ireland. His depth of experience in managing Irish corporate entities and his extensive network within the Irish business and finance community, as well as his familiarity with Irish policy and regulation, are highly beneficial to the Company as an Irish-incorporated entity. In addition to Mr. Cooke s global experience in the pharmaceutical industry, he also has significant experience in business development and transactional activities. Mr. Cooke s substantial experience as an executive in the biopharmaceutical industry, including having served as a chief financial officer and as a president of publicly-traded companies, brings strategic leadership attributes and expertise in operations, finance, and commercial management to our Board.